MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...

A lymphoma specialist who survived her own tumor surgery helps patients navigate the daunting decisions to be made.

Co., Inc. (NYSE: MRK) has initiated a pivotal Phase 3 clinical trial, waveLINE-010, to evaluate the efficacy of its investigational drug zilovertamab vedotin in treating patients with previously ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard-of-care in patients with ...

Innovative research for a dog cancer treatment from the University of Missouri College of Veterinary Medicine has shown early ...

From the death of a Netflix actress due to stomach cancer complications to an NFL star sharing his chemo experience, here is ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...